Bernard, Denzil

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 660

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 462

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 328

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 300

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

Zhao, Y., Liu, L., Sun, W., Lu, J., McEachern, D., Li, X., Yu, S., Bernard, D., Ochsenbein, P., Ferey, V., et al. (2013) · Journal of the American Chemical Society

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 234

Discovery of 4-((3′ R ,4′ S ,5′ R )-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 211

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 91

Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics

Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 72

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction

Aguilar, A., Zheng, K., Xu, T., Xu, S., Huang, L., Fernandez-Salas, E., Liu, L., Bernard, D., Harvey, K. P., Foster, C., et al. (2019) · Journal of Medicinal Chemistry

Computational Drug Discovery MethodsProtein Degradation and Inhibitors

Cited by 39

Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia

Pedicone, C., Fernandes, S., Matera, A., Meyer, S. T., Loh, S., Ha, J.-H., Bernard, D., Chisholm, J. D., Paolicelli, R. C., & Kerr, W. G. (2022) · iScience

Neuroinflammation and Neurodegeneration MechanismsProtein Tyrosine Phosphatases

Cited by 26